Core A will be responsible for providing administrative and biostatistics support for the overall program project. The Core will interact with Program management at NIAID and with the external Scientific Advisory Panel, coordinating meetings and progress reports. Budget reports and annual reports to NIH and FDA will be coordinated by Core A. It will also serve to amalgamate the investigators, their experimental findings and their ideas, evaluation of preclinical and clinical efforts to focus efforts on enhancing the clinical outcome. The administrative functions will be accomplished using a structure in which the Core Leader, Dr. Riley, is advised by an Executive Committee of Project and Core Leaders with input from the Scientific Advisory Committee. Dr. Carl June will serve as the regulatory sponsor for the clinical trial described in Project 1 will coordinate clinical operations and is responsible for interactions with private sector partners. The finances of the U19 will be organized by Mr. Mark Sudell who will meet monthly with the U19 PI and each Project and Core Leader. Dr. Shaw will provide comprehensive biostatistics support for the scientific project and core, and for the design and implementation of the clinical trial. Therefore, the specific aims are: SA1: To coordinate the interactions among scientists, private sector partners, and NIH personnel regarding efficient implementation of proposed plans and projects. SA2: To oversee all budgetary matters, including monitoring of monthly expenses and preparation of non-competitive renewal applications. SA3: To maintain records of the pre-clinical and clinical documents required by FDA and coordinate all applications/continuations to meet requirements regulatory agencies and committees. SA4: To provide statistical support for projects and the clinical trials, bioinformatics support for Project 1, and to implement the plans to promote data sharing for all projects and cores.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI117950-05
Application #
9902829
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Poon, Betty
Project Start
Project End
2021-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ecker, Christopher; Guo, Lili; Voicu, Stefana et al. (2018) Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Rep 23:741-755
Maldini, Colby R; Ellis, Gavin I; Riley, James L (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18:605-616
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Veenhuis, Rebecca T; Kwaa, Abena K; Garliss, Caroline C et al. (2018) Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 3:
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Bengsch, Bertram; Ohtani, Takuya; Herati, Ramin Sedaghat et al. (2018) Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns. J Immunol Methods 453:3-10
Fraietta, Joseph A; Nobles, Christopher L; Sammons, Morgan A et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307-312
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Clarke, Erik L; Connell, A Jesse; Six, Emmanuelle et al. (2018) T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med 10:70
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156

Showing the most recent 10 out of 27 publications